Sebela Pharmaceuticals to Present Positive Phase 3 Tegoprazan Data in Non-Erosive Reflux Disease (NERD) at the American College of Gastroenterology (ACG) 2026 Meeting

Phase 3positiveTegoprazanPositive

AI Analysis

Summary

Sebela Pharmaceuticals announced positive Phase 3 data for Tegoprazan in non-erosive reflux disease, showing clinical improvement in heartburn and regurgitation symptoms. The company will present detailed analysis at the American College of Gastroenterology 2026 Meeting.

Clinical Trial Data

Phase

Primary Endpoint

Met

Outcome Details

Tegoprazan demonstrated clinical improvement in both hallmark symptoms of NERD, heartburn and regurgitation, in a prospective U.S. phase 3 clinical trial

Importance:7/10

Sentiment:

0.75

Phase 3Positive DataGERDP-CABConference Presentation

Related Companies

$AHR $TRAX

Read the original article

Published by PR Newswire Biotech on October 11, 2026 5:00 PM

Read Original